Product Program year 2025 Source: CMS Open Payments

Nucala

Biological Immunology

NDC 0173-0881-01

Open in the dashboard

General payments

$25,386,251

319,321 payments

Research payments

$13,509,964

1,828 payments

Through program year 2025, $25,386,251 in general payments and $13,509,964 in research payments were reported against Nucala (Immunology).

No combined total These are different kinds of money, reported under different rules. A meal and a clinical trial grant do not add up to anything meaningful, so this site does not add them.

By program year

13 rows
Year Kind Amount Payments
2025 General $6,757,208 100,185
2025 Research $1,909,591 309
2024 General $3,921,037 58,907
2024 Research $1,613,398 317
2023 General $5,678,754 64,243
2023 Research $2,356,273 282
2022 General $4,905,383 54,911
2022 Research $4,546,170 475
2021 General $4,094,254 40,807
2021 Research $3,020,597 381
2020 General $14,005 146
2020 Research $63,936 64
2019 General $15,610 122

Breakdown

Who paid General payments · program years 2019–2025
  1. GlaxoSmithKline, LLC. $25,386,251 319,321 payments
Top recipients General payments · program year 2025
  1. Seth Oringher Chevy Chase, MD $134,951 2% · 118 payments
  2. Bob Geng Allergy & Immunology · San Diego, CA $134,049 2% · 95 payments
  3. Michael Ott Pulmonary Disease · Eglin Afb, FL $131,493 2% · 173 payments
  4. Michael Mandel Pulmonary Disease · Larchmont, NY $122,122 2% · 120 payments
  5. Philip Chen Otolaryngology · San Antonio, TX $121,449 2% · 91 payments

The top 5 of the 100 largest recipients; each share is of general payments naming this product in 2025.

The top 25 recipients, free in the app

Specialties paid General payments · program year 2025
  1. Pulmonary Disease Internal Medicine $2,569,196 39% · 4,015 practitioners
  2. Allergy & Immunology $1,019,746 16% · 1,557 practitioners
  3. Otolaryngology $859,993 13% · 2,236 practitioners
  4. Critical Care Medicine Internal Medicine $607,985 9% · 580 practitioners
  5. Internal Medicine $269,948 4% · 857 practitioners

The top 5 of 145 specialties; each share is of general payments naming this product to practitioners with a specialty in 2025. Each practitioner is counted under their primary specialty.

The top 25 specialties, free in the app

Where the money went General payments · program year 2025
  1. California $993,490 15% · 1,575 recipients
  2. New York $674,387 10% · 1,370 recipients
  3. Florida $525,884 8% · 1,456 recipients
  4. Texas $450,491 7% · 1,242 recipients
  5. Ohio $360,252 5% · 681 recipients

The top 5 of 51 states; each share is of general payments naming this product in 2025 where a state was reported.

The top 25 states, free in the app

Prescribed to Medicare patients

Part D · data year 2024

Part D claims

57,845

Prescriptions dispensed, refills included

Drug cost

$248,787,540

Paid at the pharmacy, in all

Prescribers

2,641

With 11 or more claims of it

Medicare Part D drugs matched to NUCALA, 2024
Part D drug Name match Relative to the largest Prescribers Claims Drug cost
Nucala Mepolizumab Same name 2,641 57,845 $248,787,540

Matched to this product by name; CMS does not link its files to Open Payments, so a similar name can be a different strength, form or brand. Prescriber counts include only prescribers with 11 or more claims of the drug, because CMS publishes nothing below that. Part D covers drugs dispensed to Medicare beneficiaries at a pharmacy; it does not include drugs given in a clinic or hospital, or patients with other insurance.

Largest prescribers

First 5 of 100 by claims · 2024

Two separate records. Claims come from Medicare and related payments from Open Payments. They are shown in one row because they name the same product; they do not show that a payment affected a prescription.

The prescribers with the most Part D claims of this drug in 2024
Prescriber Specialty State Claims Drug cost Related payments
Alec Steils Nurse Practitioner IA 203 $911,904 None on record
Vivek Sambhara Pulmonary Disease GA 187 $779,059 $23,381
Anne Holly Physician Assistant NY 179 $1,101,753 None on record
James Lampasso Pulmonary Disease NY 179 $690,513 $11,199
Matthew Varner Pulmonary Disease SC 169 $604,914 None on record

"No profile" means the prescriber has no Open Payments record here; "None on record" means no payment naming this product in the payment year. Related payments are general payments, and one that names several products is split evenly, so an amount is payments related to the product, not money paid for it. The list is the prescribers with the most claims, up to 100 per drug.

See more in the dashboard: 25 with a free account, all 100 with Patron

Given in the clinic

Part B · billing code
Medicare Part B billing codes matched to NUCALA
Billing code Providers Services Paid by Medicare
Injection, mepolizumab, 1 mg J2182 199 1,684,156 $39,614,379

Drugs given by a clinician are billed to Medicare Part B, not Part D. The product is tied to a billing code through the NDC on CMS's crosswalk, which was published for a later quarter than the payments, so a code that changed in between can be missed. Providers with fewer than 11 patients for the code are not published. Medicare's payment here is what it paid for the services, to the billing practice.

319,321 general · 1,828 research

Every payment, record by record

Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.

What you are looking at

Manufacturers name the drug, biological or device a payment relates to. CMS does not give products their own identifiers, so a product here is assembled from how it was reported — a brand may appear under more than one spelling, and this page covers one of them rather than the brand as a whole.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record